Inclisiran for the treatment of heterozygous familial hypercholesterolemia
Frederick J. Raal, David Kallend, et al. Ray KK
Abstract
Short summary: Inclisiran (a small interfering double-stranded RNA against PCSK9) is superior to placebo in reducing LDL-C among individuals with heterozygous Familial Hypercholesterolemia who are already on statins and ezetimibe.
Topics & Concepts
Familial hypercholesterolemiaMedicineHeterozygote advantageGeneticsInternal medicineBiologyCholesterolGenotypeGeneLipoproteins and Cardiovascular Health